than usual treatment times may be needed in order to achieve adequate dialysis dose in this unusual access.
Mycobacterial-immune reconstitution inflammatory syndrome: a cause of acute interstitial nephritis during HIV infection
However, up to 25% of patients starting cART experience a clinical deterioration referred to as immune reconstitution inflammatory syndrome (IRIS) [1] . Kidney injury has been exceptionally reported as a consequence of IRIS. We report such a case triggered by a non-tuberculous mycobacterial infection.
Case report
An asymptomatic 37-year-old naive HIV-1-infected white male was started in September 2009 on cART based on efavirenz, tenofovir and emtricitabine, together with cotrimoxazole chemoprophylaxis ( Figure 1 ). His CD4 + T-cell count was 25/mm 3 (4%) and plasma HIV-1 viral load (VL) 6.5 log 10 copies/mL. His estimated glomerular filtration rate (eGFR) was 106 mL/min/1.73m 2 (serum creatinine level 76 μmol/L). At Day 34 after starting cART, he was diagnosed with a Mycobacterium avium infection. An anti-mycobacterial regimen based on clarithromycin, rifabutin, moxifloxacin and amikacin was started. Clinical condition gradually improved.
He was readmitted on Day 103 after starting cART for fever, cognitive impairment and acute renal failure. Serum creatinine level reached 560 μmol/L. Urinary abnormalities consisted of mild proteinuria (1.2 g/day) with tubular profile, without evidence for proximal defects. There was neither haematuria nor eosinophilia. CD4 + T-cell count was 88/mm 3 (29%) while plasma VL had dropped to 2.4 log 10 copies/mL. Brain magnetic resonance imaging and cerebrospinal fluid analysis were normal. As compared to initial assessment, computed tomography (CT) scan revealed kidney enlargement (Figure 2A A diagnosis of non-tuberculous mycobacterial IRIS with prominent kidney involvement was made. Prednisone was started at a dose of 1 mg/kg/day for 4 weeks and then gradually tapered during the next month. Four sessions of haemodialysis were performed. Cotrimoxazole and anti-mycobacterial therapy were continued while cART was adjusted (abacavir, lamivudine, raltegravir and enfuvirtide). Fever abated and neurological manifestations improved promptly. Renal function improved over the next month. At 10 months' follow-up, serum creatinine level is 90 μmol/L (eGFR 73 mL/min/1.73m
2 ) while CD4 + T-cell count is 124/mm 3 (17%) and plasma VL < 1.3 log 10 copies/mL.
Discussion
Acute kidney injury (AKI) during HIV infection encompasses a wide variety of diseases [2] . In this case, kidney biopsy pointed to granulomatous AIN and ruled out glomerular injury, lymphoma infiltration or isolated amikacinand tenofovir-induced tubular necrosis. Drug-induced AIN was first considered since the patient was treated by cotrimoxazole and moxifloxacine. However, both treatments were pursued while kidney function improved. Massive kidney enlargement on CT scan, concomitant worsening of lymphadenitis, appearance of lung infiltrates and cognitive impairment were suggestive of a systemic inflammatory response and argued for considering another diagnosis. Interestingly, sarcoidosis may occur during immune restoration in HIV-infected patients [3] . However, the mean delay between starting cART and sarcoidosis is 29 ± 16 months, as compared to 3 months in our patient. We therefore considered that this patient developed a non-tuberculous mycobacterial IRIS that culminated in a granulomatous AIN with renal failure.
IRIS is characterized by the paradoxical worsening during immune recovery of manifestations of opportunistic infections [1] . Mycobacterial infections are the main pathogens associated with IRIS. Mycobacterial IRIS is thought to be the consequence of a recovered Th1 immune response against mycobacterial antigens that overshoots its goal IRIS-related AINand causes inflammatory tissue damage. Manifestations of mycobacterial IRIS are protean, including fever, lymphadenopathy and pulmonary, intra-abdominal or neurological manifestations [4] . The diagnosis of mycobacterial-related IRIS in the face of an inflammatory process occurring after cART initiation relies on a multiparametric assessment [1] . First, HIVinfected patients must respond positively to cART, with evidence of controlled HIV replication (decrease in plasma VL > 2 log 10 copies/mL). Second, a negative in-depth microbiological analysis must testify that the mycobacterial infection previously recognized is controlled by antimicrobial therapy. Third, newly acquired opportunistic infection or drug toxicity should be ruled out. Last, pathological demonstration of an intense immune response is suggestive of IRIS. While the lack of granuloma is a feature of mycobacterial infections in HIV-infected patients with severe immunosuppression, kidney pathology demonstrated in our case massive inflammatory and granulomatous infiltrates. This was considered as an immune-mediated tissue damage linked to the recovery of the M. avium-specific immune response.
IRIS rarely targets the kidney. So far, only five cases of biopsy-proven IRIS-related kidney injury have been reported [5] [6] [7] [8] [9] . All occurred within 4 months of cART in HIV-infected patients treated for a Mycobacterium tuberculosis co-infection. Particular to our case is that IRIS-related kidney injury was triggered by M. avium. In all cases, renal pathology demonstrated acute tubulointerstitial nephritis with mononuclear cell infiltrates mainly composed of macrophages and lymphocytes. Non-caseating granulomas were demonstrated in three patients not receiving corticosteroids prior to renal biopsy [7] [8] [9] . Immunophenotyping of infiltrates is available in one case and demonstrated prominent CD4 + T cells with few CD8 + T cells and very few B cells [5] . However, in our case, immunohistochemistry staining by demonstrating the dominance of macrophages supports the role of the innate immune system in the pathogenesis of mycobacterial IRIS.
In all cases of IRIS-related kidney injury reported so far, management was based on a short course of prednisone (1 mg/kg/day), with prompt renal response. This approach was proved efficient in a controlled clinical trial in patients with paradoxical tuberculosis IRIS [10] . Simultaneously, optimizing the anti-mycobacterial therapy is pivotal to suppressing replication of the triggering pathogen and to reduce mycobacterial antigen load. Lastly, cART interruption is not recommended, as IRIS must be balanced against the risks of AIDS progression.
IRIS should therefore be considered as a diagnosis when facing AIN following efficient cART initiation. This is mandatory in countries with high endemicity for mycobacterial infections, where increasing access to cART might enhance the prevalence of this condition, which is reversible by a short course of corticosteroids.
